American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 796-803 , May 2009

Uric Acid and Long-term Outcomes in CKD

  • Magdalena Madero, MD

      Affiliations

    • Department of Medicine, Division of Nephrology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
    • ,
  • Mark J. Sarnak, MD

      Affiliations

    • Department of Medicine, Division of Nephrology, Tufts Medical Center, Boston, MA
    • ,
  • Xuelei Wang, MS

      Affiliations

    • Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • Tom Greene, PhD

      Affiliations

    • Division of Clinical Epidemiology, University of Utah, Salt Lake City, UT
    • ,
  • Gerald J. Beck, PhD

      Affiliations

    • Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • John W. Kusek, PhD

      Affiliations

    • National Institutes of Health, Bethesda, MD
    • ,
  • Allan J. Collins, MD

      Affiliations

    • Division of Nephrology, Hennepin County Medical Center, Minneapolis, MN
    • ,
  • Andrew S. Levey, MD

      Affiliations

    • Department of Medicine, Division of Nephrology, Tufts Medical Center, Boston, MA
    • ,
  • Vandana Menon, MD

      Affiliations

    • Department of Medicine, Division of Nephrology, Tufts Medical Center, Boston, MA
    • Corresponding Author InformationAddress correspondence to Vandana Menon, MD, Division of Nephrology, Tufts Medical Center, Box 391, 800 Washington St, Boston, MA 02111

Received 15 October 2008 ,Accepted 29 December 2008.

References 

  1. Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia and risk of cardiovascular disease and overall death (A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden). Acta Med Scand. 1988;224:549–555
  2. Casiglia E, Spolaore P, Ginocchio G, et al. Predictors of mortality in very old subjects aged 80 years or over. Eur J Epidemiol. 1993;9:577–586
  3. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992 (National Health and Nutrition Examination Survey). JAMA. 2000;283:2404–2410
  4. Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort (World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases). Epidemiology. 1999;10:391–397
  5. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med. 1999;131:7–13
  6. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 2000;10:136–143
  7. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart. 1997;78:147–153
  8. Reunanen A, Takkunen H, Knekt P, Aromaa A. Hyperuricemia as a risk factor for cardiovascular mortality. Acta Med Scand Suppl. 1982;668:S49–S59
  9. Feig DI, Nakagawa T, Karumanchi SA, et al. Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int. 2004;66:281–287
  10. Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens. 2001;19:1209–1215
  11. Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension: The Olivetti heart study. J Hum Hypertens. 1994;8:677–681
  12. Nagahama K, Iseki K, Inoue T, Touma T, Ikemiya Y, Takishita S. Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res. 2004;27:227–233
  13. Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50:239–247
  14. Hsu S-P, Pai M-F, Peng Y-S, Chiang C-K, Ho T-I, Hung K-Y. Serum uric acid levels show a ‘J-shaped' association with all-cause mortality in haemodialysis patients. Nephrol Dial Transplant. 2004;19:457–462
  15. Suliman ME, Johnson RJ, Garcia-Lopez E, et al. J-Shaped mortality relationship for uric acid in CKD. Am J Kidney Dis. 2006;48:761–771
  16. Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med. 2007;167:1130–1136
  17. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691–697
  18. Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant. 2000;15:34–42
  19. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Hypouricemia and hyperuricemia in type 2 diabetes: Two different phenotypes. Eur J Clin Invest. 2001;31:318–321
  20. Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med. 1979;67:74–82
  21. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease (Modification of Diet in Renal Disease Study Group). N Engl J Med. 1994;330:877–884
  22. Strasak A, Ruttmann E, Brant L, et al. Serum uric acid and risk of cardiovascular mortality: A prospective long-term study of 83,683 Austrian men. Clin Chem. 2008;54:273–284
  23. Short RA, Johnson RJ, Tuttle KR. Uric acid, microalbuminuria and cardiovascular events in high-risk patients. Am J Nephrol. 2005;25:36–44
  24. Weiner DE, Tighiouart H, Elsayed EF, et al. The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis. 2008;51:212–223
  25. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008;19:1204–1211
  26. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension. 2003;41:1183–1190
  27. Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F. Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol. 2006;17:1466–1471
  28. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem. 1991;266:8604–8608
  29. Ohno I, Hosoya T, Gomi H, Ichida K, Okabe H, Hikita M. Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron. 2001;87:333–339
  30. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51–59
  31. Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44:642–650
  32. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med. 2005;142:342–351

 Originally published online as doi:10.1053/j.ajkd.2008.12.021 on March 23, 2009.

 Because an author of this manuscript is an editor for AJKD, the peer-review and decision-making processes were handled entirely by an Associate Editor (Peter McCullough, MD, MPH, William Beaumont Hospital) who served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

PII: S0272-6386(09)00077-8

doi: 10.1053/j.ajkd.2008.12.021

American Journal of Kidney Diseases
Volume 53, Issue 5 , Pages 796-803 , May 2009

Article Tools

* Image Usage & Resolution